Literature DB >> 32759352

QuantiFERON-TB Gold Plus with Chemiluminescence Immunoassay: Do We Need a Higher Cutoff?

Francesco Bisognin1, Giulia Lombardi2, Maria Carla Re1, Paola Dal Monte1.   

Abstract

QuantiFERON-TB Gold Plus (QFT-Plus) is the most widely used interferon gamma release assay (IGRA) for the diagnosis of latent tuberculosis infection (LTBI). The aim of this study was to compare QFT-Plus results by enzyme-linked immunosorbent assay (ELISA) on the SkyLab system with those obtained with chemiluminescence immunoassay (CLIA) on the Liaison XL analyzer. Agreement between the two assays was evaluated on 419 QFT-Plus blood samples and was found to be substantial (75.4%); higher agreement was found for positive (95.4%) and negative (80.4%) results, while most discordances were due to ELISA-indeterminate/CLIA-determinate results. According to Italian Clinical Microbiologist Association recommendations, in samples (n = 79) with a borderline result in ELISA (0.20 to 0.70 IU/ml), CLIA median values statistically increased (from 0.29 to 0.59 IU/ml for TB1 and from 0.32 to 0.60 IU/ml for TB2) but remained in the borderline range. Linear regression analysis indicated a substantial correlation between ELISA and CLIA for antigen tubes TB1 (Pearson's r = 0.8666) and TB2 (Pearson's r = 0.8728), but CLIA produced higher values than ELISA. Receiver operating characteristic (ROC) analysis showed that the optimal cutoff value in CLIA was 0.45 IU/ml for TB1 and 0.46 IU/ml for TB2. In conclusion, automated QFT-Plus with CLIA is comparable to QFT-Plus performed by ELISA. Within the linearity range of the test, CLIA detects higher quantitative values than ELISA, resulting in a higher number of determinate results and the conversion of samples that were close to the cutoff into positive borderline results. A higher cutoff for QFT-CLIA needs to be defined based on clinical diagnostic criteria.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  QuantiFERON-TB Gold Plus; agreement; chemiluminescent immunoassay; cutoff; enzyme-linked immunoassay; interferon gamma release assay; latent tuberculosis infection

Mesh:

Year:  2020        PMID: 32759352      PMCID: PMC7512183          DOI: 10.1128/JCM.00780-20

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  15 in total

1.  First independent evaluation of QuantiFERON-TB Plus performance.

Authors:  Lucia Barcellini; Emanuele Borroni; James Brown; Enrico Brunetti; Luigi Codecasa; Federica Cugnata; Paola Dal Monte; Clelia Di Serio; Delia Goletti; Giulia Lombardi; Marc Lipman; Paola M V Rancoita; Marina Tadolini; Daniela M Cirillo
Journal:  Eur Respir J       Date:  2016-02-11       Impact factor: 16.671

2.  The global prevalence of latent tuberculosis: a systematic review and meta-analysis.

Authors:  Adam Cohen; Victor Dahl Mathiasen; Thomas Schön; Christian Wejse
Journal:  Eur Respir J       Date:  2019-09-12       Impact factor: 16.671

3.  Characterization of the CD4 and CD8 T-cell response in the QuantiFERON-TB Gold Plus kit.

Authors:  Elisa Petruccioli; Teresa Chiacchio; Ilaria Pepponi; Valentina Vanini; Rocco Urso; Gilda Cuzzi; Lucia Barcellini; Fabrizio Palmieri; Daniela M Cirillo; Giuseppe Ippolito; Delia Goletti
Journal:  Int J Mycobacteriol       Date:  2016-11-11

4.  Impact of clinical sample handling and processing on ultra-low level measurements of plasma cytokines.

Authors:  Limor Cohen; Alissa Keegan; Stacy E F Melanson; David R Walt
Journal:  Clin Biochem       Date:  2019-01-08       Impact factor: 3.281

5.  Quantitative Analysis of Gamma Interferon Release Assay Response in Children with Latent and Active Tuberculosis.

Authors:  Giulia Lombardi; Roberta Petrucci; Ilaria Corsini; Maria Letizia Bacchi Reggiani; Francesca Visciotti; Filippo Bernardi; Maria Paola Landini; Salvatore Cazzato; Paola Dal Monte
Journal:  J Clin Microbiol       Date:  2018-01-24       Impact factor: 5.948

6.  Evaluation of QuantiFERON-TB Gold Plus on Liaison XL in a Low-Tuberculosis-Incidence Setting.

Authors:  E De Maertelaere; S Vandendriessche; B Verhasselt; L Coorevits; E André; E Padalko; J Boelens
Journal:  J Clin Microbiol       Date:  2020-03-25       Impact factor: 5.948

7.  Comparative evaluation of CLIA and EIA for Quantiferon-TB Gold Plus.

Authors:  Sandra Brantestig; Annica Kinnunen; Sandra Almeflo; Karin Restorp; Jenny Ahlqvist; Robert Dyrdak
Journal:  APMIS       Date:  2020-03-02       Impact factor: 3.205

8.  First characterization of the CD4 and CD8 T-cell responses to QuantiFERON-TB Plus.

Authors:  Elisa Petruccioli; Teresa Chiacchio; Ilaria Pepponi; Valentina Vanini; Rocco Urso; Gilda Cuzzi; Lucia Barcellini; Daniela Maria Cirillo; Fabrizio Palmieri; Giuseppe Ippolito; Delia Goletti
Journal:  J Infect       Date:  2016-10-04       Impact factor: 6.072

Review 9.  The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling.

Authors:  Rein M G J Houben; Peter J Dodd
Journal:  PLoS Med       Date:  2016-10-25       Impact factor: 11.069

10.  Effect of Repeated Freezing and Thawing on Biomarker Stability in Plasma and Serum Samples.

Authors:  Jae-Eun Lee; Shine Young Kim; So-Youn Shin
Journal:  Osong Public Health Res Perspect       Date:  2015-11-26
View more
  1 in total

1.  Evaluation of the Fully Automated Chemiluminescence Analyzer Liaison XL for the Performance of the QuantiFERON-TB Gold Plus Assay in an Area with a Low Incidence of Tuberculosis.

Authors:  Miguel Fernández-Huerta; Clara Moreto; Neus Vila-Olmo; Erika-Inés García de Cara; María-Celeste Basaez; Miguel Santín; Fernando Alcaide
Journal:  J Clin Microbiol       Date:  2021-07-19       Impact factor: 5.948

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.